Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
DAISY is a multicenter French clinical trial - NCT04132960 - aiming at assessing the efficacy of DS-8201a (Trastuzumab deruxtecan) monotherapy in patients with metastatic breast cancer.
Principal investigators
- Pr. Fabrice ANDRÉ ([email protected])
- Dr. Fernanda MOSELE ([email protected])
- Dr. Lusque AMELIE ([email protected])
- Dr. Thomas FILLERON ([email protected])
Data coordinators
- Dr. Marta JIMENEZ ([email protected])
- Dr. Céline MAHIER ([email protected])
This folder contains instructions and documents to be signed to get access to the data. Please see data/README.md for
more details.
Contains all the code supporting the analyses presented in the paper. See code/README.md for more details.
- Bastien JOB https://github.com/aoumess [email protected]
- Loic LE BESCOND https://github.com/loic-lb [email protected]
- Yoann PRADAT https://github.com/ypradat [email protected]